𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Construction and validation of a Parkinson's disease mutation genotyping array for the Parkin gene

✍ Scribed by Lorraine N. Clark; Eneli Haamer; Helen Mejia-Santana; Juliette Harris; Suzanne Lesage; Alexandra Durr; Sabine Janin Bs; Katja Hedrich; Elan D. Louis; Lucien J. Cote; Howard Andrews; Stanley Fahn; Cheryl Waters; Blair Ford; Steven Frucht; William Scott; Christine Klein; Alexis Brice; Hanno Roomere; Ruth Ottman; Karen Marder

Publisher
John Wiley and Sons
Year
2007
Tongue
English
Weight
70 KB
Volume
22
Category
Article
ISSN
0885-3185

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

Parkin mutations account for the majority of familial and sporadic early onset Parkinson's disease (EOPD) cases with a known genetic association. More than 100 mutations have been described in the Parkin gene that includes homozygous, compound heterozygous, and single heterozygous mutations. We have designed a Parkin mutation genotyping array (gene chip) that includes published Parkin sequence variants and allows their simultaneous detection. The chip was validated by screening 85 PD cases and 47 controls previously tested for Parkin mutations. Similar genotyping microarrays have been developed for other genetically heterogeneous diseases including age‐related macular degeneration. Here, we show the utility of a genotyping array for Parkinson's disease by analysis of 60 subjects from the Genetic Epidemiology of Parkinson Disease (GEPD) study that includes 15 early‐onset PD case probands and 45 relatives. Β© 2007 Movement Disorder Society

πŸ“œ SIMILAR VOLUMES

Translated mutation in the Nurr1 gene as
Translated mutation in the Nurr1 gene as a cause for Parkinson's disease
✍ David A. Grimes; Fabin Han; Michel Panisset; Lemuel Racacho; Fengxia Xiao; Ruobi πŸ“‚ Article πŸ“… 2006 πŸ› John Wiley and Sons 🌐 English βš– 106 KB πŸ‘ 1 views

## Abstract Multiple genes have been now identified as causing Parkinson's disease (PD). In 2003, two mutations were identified in exon 1 of the Nurr1 gene in 10 of 107 individuals with familial PD. To date, investigators have only focused on screening for these known mutations of the Nurr1 gene. A

Validation of the questionnaire for impu
Validation of the questionnaire for impulsive-compulsive disorders in Parkinson's disease
✍ Daniel Weintraub; Staci Hoops; Judy A. Shea; Kelly E. Lyons; Rajesh Pahwa; Erika πŸ“‚ Article πŸ“… 2009 πŸ› John Wiley and Sons 🌐 English βš– 91 KB

## Abstract As no comprehensive assessment instrument for impulse control disorders (ICDs) in Parkinson's disease (PD) exists, the aim of this study was to design and assess the psychometric properties of a self‐administered screening questionnaire for ICDs and other compulsive behaviors in PD. The

Validation of the MDS-UPDRS Part I for n
Validation of the MDS-UPDRS Part I for nonmotor symptoms in Parkinson's disease
✍ David A. Gallagher; Christopher G. Goetz; Glenn Stebbins; Andrew J. Lees; Anette πŸ“‚ Article πŸ“… 2011 πŸ› John Wiley and Sons 🌐 English βš– 257 KB πŸ‘ 1 views

## Abstract The UPDRS has been the main outcome measure in studies of PD. Modifications have been made to improve scale properties and represent the breadth of manifestations of PD, particularly nonmotor symptoms (NMS), resulting in the __Movement__ Disorder Society's revision of the UPDRS (MDS‐UPD

Validation of a new scale for the evalua
Validation of a new scale for the evaluation of sialorrhea in patients with Parkinson's disease
✍ Santiago Perez Lloret; Gabriel PirΓ‘n Arce; Malco Rossi; MarΓ­a Laura Caivano Neme πŸ“‚ Article πŸ“… 2007 πŸ› John Wiley and Sons 🌐 English βš– 102 KB πŸ‘ 1 views

Sialorrhea is common in Parkinson disease (PD), affecting approximately 70% to 75% of patients. Several tools for measuring saliva volume or production exist, but none are designed specifically for assessing sialorrhea-related discomfort. The objective of this study was to develop and validate a cli